Escape from treatment; the different faces of leukemic stem cells and therapy resistance in acute myeloid leukemia

N Van Gils, F Denkers, L Smit - Frontiers in oncology, 2021 - frontiersin.org
Standard induction chemotherapy, consisting of an anthracycline and cytarabine, has been
the first-line therapy for many years to treat acute myeloid leukemia (AML). Although this …

Leukemic stem cells: from leukemic niche biology to treatment opportunities

T Marchand, S Pinho - Frontiers in Immunology, 2021 - frontiersin.org
Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults. While
complete remission can be obtained with intensive chemotherapy in young and fit patients …

[HTML][HTML] Inhibition of endosteal vascular niche remodeling rescues hematopoietic stem cell loss in AML

D Duarte, ED Hawkins, O Akinduro, H Ang… - Cell stem cell, 2018 - cell.com
Bone marrow vascular niches sustain hematopoietic stem cells (HSCs) and are drastically
remodeled in leukemia to support pathological functions. Acute myeloid leukemia (AML) …

The bone marrow microenvironment–Home of the leukemic blasts

MS Shafat, B Gnaneswaran, KM Bowles… - Blood reviews, 2017 - Elsevier
Abstract Acute Myeloid Leukaemia (AML) is a genetically, biologically and clinically
heterogeneous set of diseases, which are characterised by an increased growth of …

Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development

Y Yao, F Li, J Huang, J Jin, H Wang - Experimental Hematology & …, 2021 - Springer
Despite the advances in intensive chemotherapy regimens and targeted therapies, overall
survival (OS) of acute myeloid leukemia (AML) remains unfavorable due to inevitable …

Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth

SG Kellaway, S Potluri, P Keane, HJ Blair… - Nature …, 2024 - nature.com
Abstract Acute Myeloid Leukemia (AML) is caused by multiple mutations which dysregulate
growth and differentiation of myeloid cells. Cells adopt different gene regulatory networks …

Trial Watch: Chemotherapy with immunogenic cell death inducers

E Vacchelli, F Aranda, A Eggermont, J Galon… - …, 2014 - Taylor & Francis
Accumulating evidence suggests that the clinical efficacy of selected anticancer drugs,
including conventional chemotherapeutics as well as targeted anticancer agents, originates …

Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia

EJ Libourel, CPW Klerk, Y van Norden… - Blood, The Journal …, 2016 - ashpublications.org
Venous thromboembolism is a common complication in patients with cancer, but only limited
data are available in acute myeloid leukemia (AML). In a prospective study in a cohort of 272 …

Trial watch: Chemotherapy with immunogenic cell death inducers

E Vacchelli, L Galluzzi, WH Fridman, J Galon… - …, 2012 - Taylor & Francis
The long-established notion that apoptosis would be immunologically silent, and hence it
would go unnoticed by the immune system, if not tolerogenic, and hence it would actively …

Bone marrow microenvironment as a source of new drug targets for the treatment of acute myeloid leukaemia

KA Skelding, DL Barry, DZ Theron, LF Lincz - International journal of …, 2022 - mdpi.com
Acute myeloid leukaemia (AML) is a heterogeneous disease with one of the worst survival
rates of all cancers. The bone marrow microenvironment is increasingly being recognised as …